Nexstim Competitors, Revenue, Alternatives and Pricing

Claim your profile


Helsinki, Finland
Total Funding:$36.5M
Industry:Medical Equip
Lead Investor(s):N/A

Estimated Revenue & Financials

  • Nexstim's estimated annual revenue is currently $14.1M per year.(?)
  • Nexstim's estimated revenue per employee is $251,000
  • Nexstim's total funding is $36.5M.

Employee Data

  • Nexstim has 56 Employees.(?)
  • Nexstim grew their employee count by 22% last year.
  • Nexstim currently has 1 job openings.

Nexstim is the world leader in image-guided transcranial magnetic stimulation (TMS) Founded in 2000 in Helsinki, Finland, Nexstim is committed to improving the quality of life of patients with significant unmet clinical needs by helping to preserve what is vital. Nexstim has pioneered the technology for brain diagnostics and holds the only FDA-clearances for non-invasive pre-surgical mapping with the Navigated Brain Stimulation (NBS) System for the primary motor cortex and NexSpeech® for speech and language function. NBS is recognized as the emerging standard for pre-operative direct functional mapping. NBS Makes TMS Visible Nexstim's technology introduces navigated transcranial magnetic stimulation (nTMS) for pre-surgical non-invasive mapping. The navigation is based on the patient´s MRI scan and proprietary electric field modeling, allowing the NBS System to uniquely show the location and orientation of TMS-stimuli inside the brain. NBS and NexSpeech® accurately and reliably maps the brain's vital functions like a GPS maps the globe. Nexstim offers a comfortable and safe method for brain mapping in adults or children with a diagnosis of tumor or epilepsy. The Difference is Accuracy The NBS System is as accurate as the "gold standard" of intraoperative direct cortical stimulation (DCS). Multiple papers have shown that Nexstim's NBS mappings are more accurate than fMRI and MEG. Mapping results may enable more patients to be offered a surgical option, and eliminate surgical candidates before they go into the OR. NBS data leads to better planning for a more complete tumor resection, offering smaller craniotomies and less time in the OR. Better planning leads to decreasing the risk of damage to the eloquent cortex, thereby preserving a patient's vital function.